Delivering affordable cancer care in high-income countries R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ... The Lancet Oncology 12 (10), 933-980, 2011 | 814 | 2011 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors JF Cryan, OF O'Leary, SH Jin, JC Friedland, M Ouyang, BR Hirsch, ... Proceedings of the National Academy of Sciences 101 (21), 8186-8191, 2004 | 238 | 2004 |
Characteristics of Oncology Clinical Trials: Insights From a Systematic Analysis of ClinicalTrials. gov. BR Hirsch, RM Califf, SK Cheng, A Tasneem, J Horton, K Chiswell, ... JAMA internal medicine, 1-8, 2013 | 235* | 2013 |
Surgical prehabilitation in patients with cancer: state-of-the-science and recommendations for future research from a panel of subject matter experts F Carli, JK Silver, LS Feldman, A McKee, S Gilman, C Gillis, ... Physical Medicine and Rehabilitation Clinics 28 (1), 49-64, 2017 | 222 | 2017 |
Use of dopamine-β-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs JF Cryan, A Dalvi, SH Jin, BR Hirsch, I Lucki, SA Thomas Journal of Pharmacology and Experimental Therapeutics 298 (2), 651-657, 2001 | 114 | 2001 |
Capecitabine in the management of colorectal cancer BR Hirsch, SY Zafar Cancer management and research, 79-89, 2011 | 110 | 2011 |
Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention CN Hess, MT Roe, RM Clare, K Chiswell, J Kelly, JE Tcheng, E Hagstrom, ... Journal of the American Heart Association 4 (7), e001779, 2015 | 80 | 2015 |
Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice AP Mitchell, MR Harrison, MS Walker, DJ George, AP Abernethy, ... Journal of oncology practice 11 (6), 491-497, 2015 | 79 | 2015 |
Assessing the value of patient-generated data to comparative effectiveness research L Howie, B Hirsch, T Locklear, AP Abernethy Health Affairs 33 (7), 1220-1228, 2014 | 78 | 2014 |
The impact of specialty pharmaceuticals as drivers of health care costs BR Hirsch, S Balu, KA Schulman Health Affairs 33 (10), 1714-1720, 2014 | 76 | 2014 |
Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009 MA Dinan, X Mi, SD Reed, BR Hirsch, GH Lyman, LH Curtis JAMA Oncology, 2015 | 68 | 2015 |
Management of chemotherapy-induced neutropenia: measuring quality, cost, and value MA Dinan, BR Hirsch, GH Lyman Journal of the National Comprehensive Cancer Network 13 (1), e1-e7, 2015 | 61 | 2015 |
Biosimilars: are they ready for primetime in the United States? BR Hirsch, GH Lyman Journal of the National Comprehensive Cancer Network 9 (8), 934-943, 2011 | 45 | 2011 |
Response rate as a regulatory end point in single-arm studies of advanced solid tumors GR Oxnard, KH Wilcox, M Gonen, M Polotsky, BR Hirsch, LH Schwartz JAMA oncology 2 (6), 772-779, 2016 | 44 | 2016 |
Breast cancer screening with mammography BR Hirsch, GH Lyman Current Oncology Reports 13, 63-70, 2011 | 38 | 2011 |
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review BR Hirsch, GH Lyman Pharmacoeconomics 30, 497-511, 2012 | 33 | 2012 |
Biosimilars: a cure to the US health care cost conundrum? BR Hirsch, GH Lyman Blood Reviews 28 (6), 263-268, 2014 | 32 | 2014 |
Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry MR Harrison, BR Hirsch, DJ George, MS Walker, C Chen, B Korytowsky, ... Journal of oncology practice 10 (2), e63-e72, 2014 | 31 | 2014 |
Will biosimilars gain momentum? BR Hirsch, GH Lyman Journal of the National Comprehensive Cancer Network 11 (10), 1291-1297, 2013 | 28 | 2013 |
A comparison of FDA and EMA drug approval: implications for drug development and cost of care. LJ Howie, BR Hirsch, AP Abernethy Oncology (08909091) 27 (12), 2013 | 23 | 2013 |